Compositions and kits for oral administration of a phosphodiesterase-4 (PDE4) inhibitor and one or more additional active agents that reduces or eliminates a side effect associated with the PDE4 inhibitor are provided. Also provided are methods for use of these compositions and kits for treating conditions treatable with a PDE4 inhibitor therapy and for increasing patient compliance with treatment with PDE4 inhibitors.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

The present invention discloses solid oromucosal pharmaceutical formulations containing a psychedelic selected from psilocybin, psilocin, or mescaline and/or an analog thereof as an active ingredient, a method of preparation of the pharmaceutical form by Selective Laser Sintering (SLS) 3D printing, and treatment of neurological and/or psychiatric disorders, as well as inflammatory disorders.

An oral or injectable pharmaceutical composition is provided for treating diseases caused by retroviruses or hepatitis B viruses. The composition comprises a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof. Methods and kits are also provided.

An oral adhering lozenge is provided which delivers to the mouth a component with an undesirable flavor and a component for delivering a masking flavor. The oral adhering lozenge comprises a first, adherent layer and a second layer. The first, adherent layer includes a flavor-masking component, and the second layer includes both an active component and a flavor-masking component. In another configuration, the first, adherent layer includes both an active component and a flavor-masking component. In use, the second layer of the lozenge generally finishes dissolving and/or eroding in the mouth before the first layer finishes dissolving and/or eroding. The later eroding adherent layer will continue to release the flavor-masking component after all of the active component has been released into the mouth, thereby providing increased masking of any bitter aftertaste of the active.

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.

Provided is a solid preparation comprising a controlled-release film, wherein the controlled-release film includes a dry film of an edible ink, and contains a water-insoluble polymer, and has excellent controlled-releasability of an active ingredient contained in a tablet core. The solid preparation according to the present invention comprises a tablet core, and at least one layer of a controlled-release film provided on at least a part of a surface of the tablet core, wherein the tablet core contains at least one active ingredient, and the controlled-release film includes a dry film of an edible ink containing at least one water insoluble polymer.

The present disclosure relates to a pharmaceutical composition that delayed-releases tegoprazan and releases clopidogrel immediately. The pharmaceutical composition may exhibit significantly excellent effects on the prevention and treatment of gastrointestinal disorders caused by administration of clopidogrel and thrombosis-related diseases.

The disclosure provides a multi-layered tablet configured for oral use, the tablet including a first layer including an effervescent composition and a second layer including a non-effervescent composition. The effervescent composition includes an effervescent material; one or more fillers in a total amount of at least about 30% by weight, the one or more fillers including at least one sugar alcohol; and at least one active ingredient. The non-effervescent composition includes one or more fillers in a total amount of at least about 30% by weight, the one or more fillers including at least one sugar alcohol; a binder; and a second active ingredient.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.